By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Bronchodilator combinations > Albuterol and ipratropium (inhalation) > Albuterol / Ipratropium Dosage
Bronchodilator combinations
https://themeditary.com/dosage-information/albuterol-ipratropium-dosage-7452.html

Albuterol / Ipratropium Dosage

Drug Detail:Albuterol and ipratropium (inhalation) (Albuterol and ipratropium (inhalation) [ al-bue-ter-ol-and-ip-ra-tro-pee-um ])

Drug Class: Bronchodilator combinations

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Chronic Obstructive Pulmonary Disease - Maintenance

Inhalation Aerosol:
1 inhalation (albuterol-ipratropium bromide 100 mcg-20 mcg) orally four times a day. Additional inhalations can be taken as required.
Maximum dose: 6 inhalations in 24 hours

Inhalation solution:
One 3 mL vial (albuterol-ipratropium bromide 2.5 mg-0.5 mg) four times a day via nebulization
Maximum dose: Up to 2 additional 3 mL doses per day, if needed

Comments:

  • The inhalation solution can be continued as medically indicated to control recurring bouts of bronchospasm.
  • If a previously effective regimen fails to provide the usual relief, medical advice should be sought immediately, as this is often a sign of worsening COPD and may require reassessment of therapy.

Use: In patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator

Renal Dose Adjustments

This drug has not been studied in patients with renal dysfunction. Caution is recommended.

Liver Dose Adjustments

This drug has not been studied in patients with hepatic dysfunction. Caution is recommended.

Precautions

CONTRAINDICATIONS:

  • Hypersensitivity to the active component or any of the ingredients
  • Hypersensitivity to atropine and its derivatives

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • For oral inhalation only.
  • Inhalation solution: It should be administered via jet nebulizer connected to an air compressor with an adequate air flow, equipped with a mouthpiece or suitable face mask.
  • Inhalation aerosol: Prior to first use or if not used for more than 21 days, prime the device by spraying the inhaler toward the ground until an aerosol cloud is visible and then repeat the process three more times. If not used for more than 3 days, spray the inhaler once before use.
  • Safety and efficacy of additional doses, extra doses, or increased frequency of administration beyond the recommended doses has not been studied. DO NOT use more frequently than recommended.
  • The manufacturer product information should be consulted.

Monitoring:
  • Metabolic: Potassium levels
  • Ocular: Patients with narrow-angle glaucoma

Patient advice:
  • Avoid spraying into the eyes as it may result in precipitation or worsening of narrow angle glaucoma, mydriasis, increased intraocular pressure, acute eye pain or discomfort, temporary blurring of vision, visual halos or colored images in association with red eyes from conjunctival and corneal congestion. Consult a physician immediately if any of these symptoms occur.
  • Use with caution when engaging in activities requiring balance and visual acuity such as driving a car or operating appliances or machinery.
  • Consult a physician if experiencing difficulty urinating.
  • If the treatment becomes less effective for symptomatic relief, symptoms become worse, and/or need to use the product more frequently than usual, medical attention should be sought immediately.
  • Other inhaled drugs should be taken only as directed by a physician while in treatment with this combination drug.
Share this Article
Latest News
Medical News

Ozempic, Wegovy: 4 factors may influence weight loss results

Jul 12, 2025
Breast cancer after menopause: Do weight, heart disease affect risk?
Aging: Long-term Mediterranean diet may not improve cognition in all
Is it ever safe to eat processed meat? Latest research answers 'no'...
Colorectal, gastric cancers: Why are they occurring earlier in life?
Rheumatoid arthritis: Could a test tell which biologic may be best?
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by